This report examines the impact of graft composition on outcomes in 130 patients with hematological malignancies given unrelated donor granulocyte-colony-stimulating-factormobilized peripheral blood mononuclear cells (G-PBMC) (n ¼ 116) or marrow (n ¼ 14) transplantation after nonmyeloablative conditioning with 90 mg/m 2 fludarabine and 2 Gy TBI. The median number of CD34 þ cells transplanted was 6.5 Â 10 6 / kg. Higher numbers of grafted CD14
Introduction
To extend allogeneic hematopoietic cell transplantation (HCT) from unrelated donors (URD) to older patients and those with comorbid conditions, reduced intensity or truly nonmyeloablative conditioning regimens have been developed [1] [2] [3] [4] [5] [6] in which the burden of tumor eradication has been shifted from the highdose chemoradiotherapy agents to cell-based graft-versus-tumor effects. 7 Based on experimental canine studies 8 and subsequent clinical trials in HLA-identical sibling recipients, 9 a nonmyeloablative regimen was developed for URD HCT that utilized minimal host conditioning with fludarabine and 2 Gy total body irradiation (TBI), 5, 10, 11 combined with postgrafting immunosuppression consisting of mycophenolate mofetil (MMF) and cyclosporine (CSP). We previously reported early data from 89 patients with advanced hematologic malignancies given unrelated grafts after nonmyeloablative conditioning. 5 Sustained engraftment was observed in 60 of 71 (85%) of G-CSFmobilized peripheral blood mononuclear cell (G-PBMC) recipients and in 10 of 18 (56%) of marrow recipients. 5 Over 40% of patients with measurable disease at the time of HCT achieved complete remissions, and 2-year progression-free survival (PFS) was 42% for G-PBMC recipients.
The focus of the current study was to determine whether the dose of total nucleated cells (TNC) and/or specific cell subtypes in the unrelated grafts were associated with clinical outcomes in 130 consecutive patients given unrelated grafts after nonmyeloablative conditioning for hematologic malignancies. The eventual aim was to determine whether prospective manipulations of the graft composition might be useful to improve HCT outcomes in patients with hematologic malignancies given URD HCT after nonmyeloablative conditioning.
Patients and methods

Patients
Included in the study were results from 130 consecutive patients with hematologic malignancies given allogeneic HCT after nonmyeloablative conditioning on prospective research protocols between January 2000 and December 2003 at the Fred Hutchinson Cancer Research Center (FHCRC), the University of Washington Medical Center, the Children's Hospital and Regional Medical Center and the Veterans Affairs Puget Sound Health Care System (all in Seattle, WA, USA). Data were analyzed as of 31 March 2004. The median follow-up for surviving patients was 531 (range, 93-1475) days. Patients were considered ineligible for conventional allogeneic HCT because of age (450 years) and/or comorbidities, or preceding extensive therapies such as a myeloablative autologous or allogeneic HCT. 5 Reasons for nonmyeloablative conditioning for the 46 patients younger than 50 years (including five patients younger than 16 years) were previous high-dose myeloablative allogeneic (n ¼ 3), syngeneic (n ¼ 1) or autologous (n ¼ 27) HCT, abnormal liver function tests with or without chronic renal failure (n ¼ 5), cardiomyopathy (n ¼ 2), active mycotic infections (n ¼ 2), chronic renal failure (n ¼ 1), morbid obesity (n ¼ 1), chronic leg ulcerations (n ¼ 1), cavernous arteriovenous malformation (n ¼ 1), hypoxemia (n ¼ 1), and patient decision (n ¼ 1). Characteristics of the patients are summarized in Table 1 .
Median patient age was 54 (range, 5-71) years. Patients were classified as being at standard-risk, high-risk or very high risk for disease progression after HCT as described in Table 1 . Pretransplant comorbidities were determined from the patients' pretransplant evaluation notes and scored using a template adapted from the Charlson Comorbidity Index, as previously reported. 12, 13 Compatibility between patients and donors for HLA-A, -B, and -C antigens was assessed by intermediate-resolution DNA typing to a level at least as sensitive as serology and for -DRB1 and -DQB1 by high-resolution techniques. 5 In total, 10 patients received 1 HLA-antigen-mismatched (three of these also had single HLA-allele-mismatches) transplants, and 11 had one HLA-allele-mismatched donors.
Prospective research protocols and the current study were approved by the Institutional Review Board of the FHCRC for the participating institutions. All patients signed informed consents for the original prospective research protocols.
Conditioning regimen, postgrafting immunosuppression, and HCT collection
All patients were conditioned with fludarabine 30 mg/m 2 /day on days À4, À3, and À2, and 2 Gy TBI delivered at 0.07 Gy/min before URD donor HCT (day 0). Postgrafting immunosuppression included MMF, 15 mg/kg orally twice a day (n ¼ 51) 5 or thrice a day (n ¼ 79) from the evening of day 0 until day þ 40, Standard risks were defined as acute myeloid leukemia in first complete remission, acute lymphoblastic leukemia in first complete remission, myelodysplastic syndrome-refractory anemia, chronic myeloid leukemia in first chronic phase, chronic lymphocytic leukemia, low-grade nonHodgkin's lymphoma, high or intermediate grade non-Hodgkin's lymphoma in complete remission, Hodgkin's disease in complete remission, multiple myeloma in complete remission or with minimal residual disease; very high-risks were defined as acute leukemia above second complete remission, chronic myeloid leukemia in accelerated phase or blast crisis, and myelodysplastic syndrome-refractory anemia with blast excess or above; all other diagnoses were classified as high risk.
Impact of graft composition after unrelated HCT F Baron et al and CSP, 6.25 mg/kg orally twice a day from day À3 to day þ 100. In the absence of GVHD, MMF was tapered at day 40 (day 96 in class 1 HLA-mismatched recipients) over 56 days and CSP was tapered at day 100 (180 in class 1 HLA-mismatched recipients) over 180 days. Donor G-PBMC were generally mobilized using G-CSF (10 mg/kg/day; day À5 to À1), and collected as per the National Marrow Donor Program (NMDP) standard for donors collected in the US (n ¼ 96), or according to recommendations from other National Donor Programs for donors collected outside of the US (n ¼ 20). In total, 10% of the collected G-PBMC were set aside for cryopreservation for use as DLI, if needed. The remaining cells were infused intravenously on day 0. In total, 28 patients (including three children o15 years old) received G-PBMC obtained in one apheresis collection. No patients were given product of more than two leukaphereses. In total, 24 liters of apheresis collection was prescribed by the transplant center according to HCT protocols, but the decision to perform one or two collections was at the discretion of the collection centers. A total of 14 patients received donor marrow harvested by multiple aspirations from the posterior iliac crests on day 0.
Follow-up
Diagnosis, clinical grading, and treatment of GVHD were performed as previously reported. 5 Standard prophylaxis against infections was used. 5 Patients were examined by a healthcare provider at least three times a week for the first month and then at least weekly. Disease-dependent restaging evaluations after HCT occurred monthly for the first 3 months and then at 6 months, 1 year, and then yearly thereafter. 5 Treatment of persistent/progressive or relapsed diseases and prevention of graft rejection Progressive or relapsed malignancies in the absence of severe manifestations of acute and chronic GVHD were treated by rapid discontinuation of systemic immunosuppression in order to initiate graft-versus-tumor effects. In addition, three patients received DLI 14 for disease progression, poor T-cell chimerism, and Epstein-Barr virus-associated lymphoproliferative disease in donor cells, respectively.
Graft cell subsets enumeration
Enumerations of cell subsets in each graft product were performed by 3-color analyses using a FACScan cytometer (Becton Dickinson [BD], San Jose, CA, USA) by the Cellular Therapy Laboratory at the FHCRC. Samples from grafts were stained with monoclonal antibodies (all from BD) directed against the following surface antigens: CD3, CD4, CD8, CD14, CD20, CD34, and CD56. At least 100 000 events were acquired per sample. Gates were set around forward vs side scatter and low 7-amino-actinomycin D staining to include only viable nucleated cells for further analysis. Cell types were defined as follows: CD3
, and CD34 cells (CD34 þ CD14 -). List mode data were analyzed with either WinList (Verity Software House Inc., Topsham, ME, USA) or CellQuest (BD) software to determine percentages of cell types. Percentages were multiplied by the TNC counts of the grafts, determined by use of an NE8000 Sysmex (TOA Kobe, Japan) automated cell counter, and volume infused to determine absolute cell numbers, and divided by actual recipient weight in order to determine cell doses per kg.
T-cell chimerism analyses
For T-cell chimerism analyses, T cells were isolated from the peripheral blood by flow cytometry using a Vantage SE cytometer (BD) on days 28, 56, 84, 180, 365, and then yearly after HCT. Percentages of donor-host chimerism for recipients of sex-mismatched HCT were evaluated by fluorescent in situ hybridization (FISH) for X and Y chromosomes, or by polymerase chain reaction (PCR)-based amplification of variable-number tandem repeat (VNTR) sequences if patients and donors were sex-matched. 5 Quantification of chimerism using VNTR was by visual inspection or silver-stained agarose gel with a standard error of 5%. 5 
Statistical methods
In order to assess the association of cell-type variables with outcome, non-cell-type variables were first examined using regression models and then used to create a base model for each outcome. The non-cell-type variables used for day 28 T-cell chimerism levels, cumulative incidence of achieving full donor chimerism, and risk for graft rejection were prior chemotherapy or not (agents such as chlorambucil, hydroxyurea, imatinib mesylate or immunomodulators were classified in the 'nonchemotherapy' group), and tandem autologous/allogeneic HCT. For acute and chronic GVHD, the non-cell type variables were patient age, degree of HLA-compatibility, female donor to male recipient, CMV serostatus, myeloid or lymphoid malignancies, MMF twice a day vs thrice a day, and Charlson's comorbidity index score at transplantation. For overall survival (OS), PFS, relapse and nonrelapse mortality the non-cell-type variables were Charlson's comorbidity index score at transplantation, disease risk and tandem autologous/allogeneic HCT. Cox regression models were used for the outcomes of achievement of full donor T-cell chimerism, relapse/disease progression, acute and chronic GVHD, PFS, OS, and nonrelapse mortality. A linear regression model was used for the outcome of day 28 Tcell chimerism. In all models, cell doses were modeled as ordinal variables defined by quartile of dose. Means and hazard ratios thus refer to effects per quartile of dose, and P-values are interpretable as tests for trend. Spearman rank correlation coefficient was used to estimate the correlation between cell types. All P-values are two-sided, and no adjustments were made for multiple comparisons; thus, values between 0.01 and 0.05 should therefore be considered as suggestive rather than definitive evidence of a significant association. Table 1 shows the absolute numbers of TNC, CD34 Associations between graft composition and HCT outcomes in the entire 130 cohort of patients: Day-28 T-cell chimerism levels were available for 126 of the 130 patients. In multivariate analyses, high numbers of CD14
Results
Cellular composition of grafts
, and CD34 þ (P ¼ 0.0001) cells in the grafts were associated with high levels of day-28 donor Tcell chimerism, while high numbers of CD14 þ (P ¼ 0.01) and CD34 þ (P ¼ 0.0003) cells were associated with higher probabilities of achieving full donor chimerism levels in timedependent analyses ( Table 2) . Six of 14 marrow recipients, and eight of 116 G-PBMC (P ¼ 0.001) recipients rejected their grafts.
One of 11 patients given grafts from a one HLA allele mismatched donor (this patient had CML and was given marrow) and none of 10 patients given grafts from one HLA antigen mismatched donors rejected their grafts, compared to 13 of 109 patients (12%) given grafts from 10 of 10 HLA allele-level matched donors. In multivariate analyses, high numbers of infused CD8 þ (P ¼ 0.005) and CD34 þ (P ¼ 0.01) cells were associated with lower probabilities of graft rejection. There were no associations between any cell subsets and acute or chronic GVHD nor relapse/progression, but there was a trend for better PFS with higher cell doses transplanted for all cell type variables, and the association was significant for TNC (HR 0.8 (95% CI, 0.6-0.9), P ¼ 0.01). Similarly, there was a trend for better overall survival with higher cell doses transplanted for all cell type variables, and the association was significant for TNC (HR 0.7 (95% CI, 0.5-0.9), P ¼ 0.006).
Low day-28 donor T-cell chimerism levels predicted subsequent graft rejection
Four patients rejected their HCT (o5% donor T-cell chimerism) before day 28. In the remaining 122 patients studied, day-28 donor T-cell chimerism levels were predictive of the subsequent risk of graft rejection. Seven of 10 (70%) patients with donor T-cell chimerism levels between 5-25%, one of eight (13%) patients with levels between 26 and 50%, two of 17 (12%) patients with levels between 51 and 75% and 0 of 87 (0%) patients with levels between 75 and 100% rejected their grafts (Po0.0001) (Figure 1a) . Table 2 Impact of graft composition on T-cell chimerism and risks of graft rejection among all patients or restricted to G-PBMC recipients All P-values were two-sided, and no adjustments were made for multiple comparisons; values between 0.01 and 0.05 should be considered as suggestive for a difference rather than definitive.
c HR per quartile of dose; adjusted for prior chemo or not, and planned autologous-allogeneic HCT or not. bold ¼ statistically significant.
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Analyses restricted to G-PBMC recipients (n ¼ 116)
Associations between graft composition and donor T-cell engraftment: In multivariate analyses, high numbers of CD4 þ (P ¼ 0.007) and CD34 þ (P ¼ 0.01) cells in the grafts were associated with high levels of day-28 donor T-cell chimerism (Table 2) . Full donor T-cell chimerism levels (defined as X95% donor T-cells) were achieved in 97 G-PBMC recipients between 22 and 105 (median 35) days after HCT. In multivariate analyses, there was a suggested association between high number of CD34 þ cells and achievement of full donor chimerism (P ¼ 0.02).
Associations between graft composition and graft rejection: In multivariate analysis, high numbers of infused CD8 þ (HR 0.5, P ¼ 0.12) and CD34 þ (HR 0.6, P ¼ 0.14) cells were suggestively associated with lower probabilities of graft rejection, although these associations lacked statistical significance, probably as a result of the small number of graft rejections among G-PBMC recipients (n ¼ 8) (Table 2 ). In addition, patients given G-PBMC containing more than the median CD34
þ cells dose (6.8 Â 10 6 /kg) had a strong trend for a lower risk of graft rejection in comparison to patients given less than the median number of CD34 þ cells (HR 0.2 (95% CI, 0.0-1.4, P ¼ 0.10)).
Associations between graft composition and graftversus-host disease (GVHD): Acute GVHD of grades II, III, and IV occurred in 64 (55.2%), 16 (13.8%), and 2 (1.7%) patients, respectively. In multivariate analyses, none of the cell-type variables were statistically significantly associated with grades II-IV or III-IV acute GVHD (P-values ranged from 0.48 to 0.98).
Chronic GVHD requiring systemic therapy was seen in 70 patients. In multivariate analyses, none of the cell-type variables were statistically significantly associated with extensive chronic GVHD (P-values ranged from 0.12 to 0.69) (Figure 1b and c) .
Relapse/progression and nonrelapse mortality: In total, 42 of 116 patients (36%) relapsed/progressed after HCT. Only one of the 42 patients was given DLI. In the remaining patients, DLI were contraindicated due to graft rejection (n ¼ 5), or because of GVHD preceding (n ¼ 14) or occurring soon after (n ¼ 3) disease progression. Further, DLI was not offered to eight patients with florid relapse, two patients who relapsed o50 days after HCT, and five patients with CML (n ¼ 2), CLL (n ¼ 2) and MDS, respectively, who achieved complete remissions after withdrawal of immunosuppression. Finally, two patients refused DLI, and two patients were given either imatinib or thalidomide instead of DLI for CML and myeloma relapses, respectively, after HCT. In multivariate analysis, none of the cell variables was significantly associated with relapse/progression.
In total, 19 patients (16%) died of nonrelapse causes. In multivariate analysis, none of the cell variables was significantly associated with nonrelapse mortality.
Progression-free and overall survival
The probabilities of PFS at 1, 2, and 3 years were 49, 43, and 33%, respectively. In multivariate analyses, there was a trend for better PFS in patients given higher number of TNC (HR 0.8 (95% CI, 0.7-1.1), P ¼ 0.13), although the association was not statistically significant.
The probabilities of OS at 1, 2, and 3 years were 62, 52, and 43%, respectively. In multivariate analyses, there was a trend for better OS in patients given higher number of TNC (HR 0.8 (95% CI, 0.6-1.0), P ¼ 0.06), although the association was not statistically significant.
Discussion
The present study asked whether the individual cell subsets in unrelated, unmanipulated hematopoietic grafts affected outcomes among patients given nonablative conditioning. Our key findings were as follows. Higher numbers of grafted T-cells (including CD4
þ , CD8 þ , and CD3 þ CD56 þ T-cell subsets), Impact of graft composition after unrelated HCT F Baron et al CD14 þ cells, NK cells, and CD34 þ cells were associated with higher levels of donor T-cell chimerism, while high CD14 þ and CD34 þ contents were associated with more rapid achievement of complete donor T-cell chimerism, and high T-cell (including CD8 þ and CD3 þ CD56 þ T-cell subsets), monocyte, and CD34 þ cell numbers reduced the risk of graft rejection. Among T-cell subsets, both CD4 þ and CD8 þ T cells might promote T-cell engraftment, confirming previous observations in a canine model 15 and in patients given HCT after myeloablative 16, 17 or nonmyeloablative conditioning. 18, 19 Furthermore, since CD14 þ cells contained in G-PBMC grafts secrete large amounts of IL-10 (an immunosuppressive cytokine) and have reduced expression of costimulatory molecules needed for T-cell activation, those cells might provide immunosuppressive effects that reduce host-versus-graft (rejection) reactions. 20 The role of CD3 þ cells for the development of acute and chronic GVHD after allogeneic HCT has been established. 16 However, we found no statistical correlation between CD3 þ (including CD4 þ and CD8 þ subsets) cell doses and the risk of acute GVHD. This was consistent with previous studies showing comparable risks of acute GVHD in patients with aplastic anemia, of whom some did and some did not receive infusions of viable donor buffy coat cells in addition to marrow grafts after conditioning with cyclophosphamide. 21 Also, several studies reported similar incidences of acute GVHD after G-PBMC and marrow grafts despite the infusion of 1 to 2 logs more CD3 þ cells in the G-PBMC inocula. 22, 23 Perhaps, as suggested by Kernan et al, 24 once an initial threshold (
þ cells has been exceeded, further increases in T-cell numbers do not necessarily translate into more acute GVHD for given degrees of genetic disparity between donors and recipients.
In the current study, higher doses of CD34 þ and CD3 þ cells were not associated with increased risks of chronic extensive GVHD. These results were in agreement with previous observations in unrelated graft recipients after myeloablative conditioning, 25 but contrasted with findings in related ablative 26, 27 and nonablative 28 recipients that showed a positive correlation between numbers of CD34 þ cells and incidence of chronic extensive GVHD, and also the finding of a higher incidence of chronic GVHD in patients with aplastic anemia given donor buffy coat cells in addition to related marrow grafts. 21 The reasons for the differences among related and unrelated recipients are unclear. Perhaps, greater disparity for minor histocompatibility antigens in the unrelated setting could lead to more chronic GVHD. In addition, it might be that there were thresholds for CD34 þ and CD3 þ cell doses above which correlations between graft composition and chronic GVHD no longer existed. These thresholds might be lower in unrelated recipients because of greater minor histocompatibility antigen divergences than in related recipients. 29 However, one recent study also failed to find a correlation between high CD34 þ cell dose and high incidence of chronic GVHD in patients given related G-PBMC after nonmyeloablative conditioning. 30 The current observations suggested that there is no upper cell dose limit for patients given unrelated G-PBMC after nonmyeloablative conditioning with fludarabine and 2 Gy TBI. 30 When data from all patients were analyzed, there were trends for better PFS and OS with higher cell doses for all cell type variables, and that association was significant for TNC. This observation agreed with previous reports demonstrating better PFS in unrelated recipients given higher nucleated cell doses after myeloablative conditioning. 31, 32 A similar trend for better PFS in patients receiving a higher number of TNC was observed when analyses were restricted to G-PBMC recipients, although the association was no longer statistically significant. However, the current study failed to show a correlation between higher CD8 þ cell doses in G-PBMC and better PFS (HR ¼ 0.9, P ¼ 0.42) or OS (HR ¼ 0.9, P ¼ 0.27), as recently proposed by Cao et al 19 in patients given a similar nonmyeloablative conditioning and postgrafting immunosuppression. That study analyzed combined observations in 25 patients given G-PBMC from URD and 38 recipients of related grafts, which may explain the discrepancy with the current study in unrelated recipients. A recent study from our group analyzed the impact of graft composition in 120 patients given G-PBMC from related donors after nonmyeloablative conditioning, and showed better OS (P ¼ 0.03) in patients given a higher number of CD34 þ cells in the grafts, but no correlations between CD8 þ cells contents and HCT outcomes. 30 In conclusion, our data suggested that giving higher doses of CD34 þ cells helped to promote sustained T-cell engraftment in patients given unrelated grafts after nonmyeloablative conditioning without increasing the risks for acute or chronic GVHD, and therefore, as many CD34 þ cells as possible should be collected from the donors.
